{{Rsnum
|rsid=10733113
|Chromosome=1
|position=247459055
|Orientation=plus
|GMAF=0.1662
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 21.2 | 77.0
| HCB | 0.0 | 7.3 | 92.7
| JPT | 1.8 | 19.5 | 78.8
| YRI | 8.8 | 36.1 | 55.1
| ASW | 14.0 | 50.9 | 35.1
| CHB | 0.0 | 7.3 | 92.7
| CHD | 0.9 | 9.3 | 89.8
| GIH | 2.0 | 9.9 | 88.1
| LWK | 6.4 | 46.8 | 46.8
| MEX | 0.0 | 38.6 | 61.4
| MKK | 11.6 | 41.9 | 46.5
| TSI | 2.9 | 27.5 | 69.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10733113
|Name_s=
|Gene_s=OR2B11
|Feature=
|Evidence=PubMed ID:19098911
|Annotation=In a candidate gene approach this SNP on chromosome 1q44 downstream of NLRP3 was strongly associated with risk of Crohn's disease.
|Drugs=
|Drug Classes=
|Diseases=Crohn Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162363872
}}

{{omim
|desc=NLR FAMILY, PYRIN DOMAIN-CONTAINING 3; NLRP3
|id=606416
|rsnum=10733113
}}

{{omim
|id=266600
|rsnum=10733113
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10733113
|overall_frequency_n=106
|overall_frequency_d=124
|overall_frequency=0.854839
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=90
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23547871
|Title=Genetic variants in CARD8 but not in NLRP3 are associated with ankylosing spondylitis
}}

{{PMID Auto
|PMID=23171454
|Title=Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}